Clinical Trial Search

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 6; 5; 0; 3 participants

Primary: Confirmed Response Rate (Complete Response and Partial Response) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) (Phase II Patients Only) — 19; 20…

Primary: Percentage of Participants With Dose Limiting Toxicities — 16.7; 0.0; 0.0; 0.0 Percentage of participants

Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 1; 1; 2; 7 participants with any solicited AE

Primary: Change From Baseline in Decisional Conflict Scale Scores — 21.80; 12.69 units on a scale — p=0.005

Primary: Picture Naming — 10.3; 12.57; 12.1; 11.14 number of pictures — p=<0.028

Primary: Number of Participants Who Completed the Study Dental Procedure Without Need for Rescue by Injection of Local Anesthetic. — 88; 14 participants

Primary: Primary Outcome: Change in Body Weight — 9.6 kg

Primary: State-Trait Anxiety Inventory Score — 40.0; 43.3 units on a scale

Primary: Primary Safety Outcome Measure: Survival Defined as Survival Free From All Cause Death at 6 Months Postprocedure — 100 percentage of participants

Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12 — 7.90; 7.97; 7.91; 7.88 percentage of hemoglobin — p=0.4468

Primary: Percentage of Participants With Any Adverse Event (AE) — 93.3; 6.7; 93.3; 80.0 percentage of participants

Primary: Change From Baseline in 24-Hour Mean Heart Rate Post-dose — -0.19; -1.84; 0.40; -0.09 bpm

Primary: Percentage of Patients With Index Event Safety Outcomes (Ongoing/Resolved/Deceased) at Time of Hospital Discharge — 19.1; 76.8; 4.1 Percentage of participants

Primary: Change From Baseline in Functional Assessment of Cancer Therapy-Lung Total Outcome Index Score at 3 Months — 2.7; 4.7 units on a scale